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Cannabis legalization has led to significant health consequences, particularly to patients in 
emergency departments and hospitals in Colorado. The most concerning include psychosis, 
suicide, and other substance abuse. Deleterious effects on the brain include decrements in 
complex decision-making, which may not be reversible with abstinence. Increases in fatal motor 
vehicle collisions, adverse effects on cardiovascular and pulmonary systems, inadvertent pediatric 
exposures, cannabis contaminants exposing users to infectious agents, heavy metals, and 
pesticides, and hash-oil burn injuries in preparation of drug concentrates have been documented. 
Cannabis dispensary workers (“budtenders”) without medical training are giving medical advice that 
may be harmful to patients. Cannabis research may offer novel treatment of seizures, spasticity 
from multiple sclerosis, nausea and vomiting from chemotherapy, chronic pain, improvements in 
cardiovascular outcomes, and sleep disorders. Progress has been slow due to absent standards 
for chemical composition of cannabis products and limitations on research imposed by federal 
classification of cannabis as illegal. Given these factors and the Colorado experience, other states 
should carefully evaluate whether and how to decriminalize or legalize non-medical cannabis use. 
[West J Emerg Med. 2019;20(4)557–572.]
INTRODUCTION
As of January 2018 in the United States, nine states 
have legalized cannabis for recreational use, with another 29 
legalizing it for medical use. These policy changes have created 
broad interest in understanding the effects on public health and 
the healthcare system. 
The Colorado Department of Public Safety report, “Impacts 
of Marijuana Legalization in Colorado: A Report Pursuant 
to Senate Bill 13-283,” includes a timeline for marijuana 
legalization in Colorado with five distinct periods in both 
the legal status and commercial availability of marijuana in 
Colorado.1 These include the following:
•	 Prior to 2000: It is illegal to possess or grow marijuana.
•	 2000-2009: Amendment 20 is approved and medical 
marijuana is legalized. The Colorado Department of 
Public Health and Environment (CDPHE) issues registry 
identification cards to individuals who have received 
recommendations from a doctor that marijuana will help a 
debilitating medical condition. No regulated market exists. 
Individual grow operations or caregiver grow operations 
University of New Mexico, Department of Emergency Medicine, Albuquerque, New Mexico
Partner, Southern Colorado Emergency Medicine Associates, Pueblo, Colorado
limited to five patients are allowed.
•	 2010-2012: Medical marijuana is commercialized and 
regulated with licensed dispensaries, grow operations, 
and product manufacturers open in jurisdictions allowing 
these types of businesses. This corresponded with the 
Ogden memorandum issued in October 2009, which 
instructed U.S. Attorneys not to “focus federal resources 
in your States on individuals whose actions are in clear 
and unambiguous compliance with existing state laws 
providing for the medical use of marijuana.”2 The 
commercialization of medical marijuana followed and 
the number of patients registered with CDPHE increased 
dramatically from about 5000 in 2009 to almost 119,000 
in 2011. 
•	 2013: Amendment 64 takes effect. Personal possession and 
grow limits for recreational marijuana are in place but sales 
are not commercialized. Medical continues as a regulated, 
commercial market. 
•	 2014 to present: Recreational and medical marijuana 
is fully regulated and commercialized. Licensed retail 
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Population Health Research Capsule
What do we already know about this issue?
Legalized cannabis has led to increased 
cannabis related presentations to emergency 
departments (ED).
What was the focus of this review?
The negative impacts to EDs, particularly 
in the state of Colorado, following cannabis 
legalization.
What was the conclusion of this review?
Cannabis legalization has been correlated with 
multiple adverse outcomes that impact EDs.
How does this improve population health?
Healthcare policy makers may take 
the adverse outcomes described into 
consideration when considering if and/or how 
to legalize cannabis.
stores open January 1, 2014. This corresponded with 
the Cole memorandum, which gave further guidance 
to U.S. Attorneys: “[I]n jurisdictions that have enacted 
laws legalizing marijuana in some form and that have 
also implemented strong and effective regulatory 
and enforcement systems to control the cultivation, 
distribution, sale, and possession of marijuana, conduct in 
compliance with those laws and regulations is less likely 
to threaten federal priorities… [E]nforcement of state law 
by state and local law enforcement and regulatory bodies 
should remain the primary means of addressing marijuana-
related activity.”3 This memorandum was widely 
interpreted to mean that the federal government would not 
interfere with state marijuana laws;4 however, in January 
2018 the Cole memorandum was rescinded by then U.S. 
Attorney General Jeff Sessions.4 
Changes in past-month cannabis use by year and age group 
for Colorado and Kansas (non-legalized state) are shown in 
Figures 1 and 2. (Kansas was chosen for proximity; other non-
legalized states in proximity, including Wyoming and Idaho, had 
similar graphs to Kansas.)5
Over this time span cannabis potency has increased. Current 
commercialized cannabis is near 20% tetrahydrocannabinol 
(THC), the primary psychoactive constituent of cannabis, while 
in the 1980s concentration was <2%. This 10-fold increase in 
potency does not include other formulations such as oils, waxes, 
and dabs, which can reach 80-90% THC.6 
This general increase in cannabis use and increase in 
cannabis potency has led to cannabis-related presentations to 
emergency departments (ED) and hospitalizations across the 
state. This review will focus on negative health and safety 
effects Colorado has experienced with inclusion of relevant peer-
reviewed literature. It will conclude with a short review of the 
medicinal use of cannabis products.
Cannabis Effects on Healthcare Resources in Colorado
ED visits and hospitalizations with marijuana-related 
billing codes have increased following legalization. Mental 
Figure 1. Marijuana use in the past month in Colorado, by age group.
Reproduced from Substance Abuse and Mental Health Services Administration National Survey on Drug Use and Health: State 
Estimates. Available at: https://pdas.samhsa.gov/saes/state. Accessed November 2018.
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illness represents a concerningly large number of marijuana-
related visits. A retrospective review by Wang et al. reported 
Colorado Hospital Association hospitalizations and ED visits 
with marijuana-related billing codes. Between 2000 and 2015, 
hospitalization rates increased 116% from 274 to 593 per 100,000 
hospitalizations. For primary diagnosis categories, the prevalence 
of mental illness was five-fold higher (5.07; 95% confidence 
interval [CI], 4.96 - 5.09) for ED visits and nine-fold higher 
(9.67; 95% CI, 9.59 - 9.74) for hospital admissions for patients 
with marijuana-related billing codes compared to those without.7 
This data compared diagnostic categories between patients with a 
marijuana-related diagnostic code and those without.
Subsequent data by the CDPHE show significant increases 
in hospitalizations in each phase of marijuana legalization, 
increasing from 575 per 100,000 hospitalizations in 2000 to 2413 
in the 2014–June 2015 period, as displayed in Figure 3.8 There 
are differences in incidence between the Wang study and the 
CDPHE report because the Wang study only included a patient’s 
healthcare event if a marijuana code was among the first three 
diagnostic codes, while the CDPHE study included marijuana 
diagnostic codes within the top 30. 
ED and urgent care (UC) visits with cannabis-associated 
International Classification of Diseases (ICD) codes or positive 
urine drug screens for teenagers and young adults have increased 
since legalization, and the majority require behavioral health 
evaluation. A subsequent retrospective review by Wang et al. 
from 2005-2015 identified 4202 such visits for patients 13 to < 21 
years old to a tertiary-care children’s hospital system. Behavioral 
health evaluation was obtained for 2813 (67%) and a psychiatric 
diagnosis was made for the majority (71%) of the visits. ED/
UC visits with cannabis-associated ICD codes or positive urine 
drug screens of all types increased 2.7-fold from 1.8 per 1000 in 
2009 to 4.9 per 1000 in 2015 (N = 161 in 2005 to 777 in 2015). 
Behavioral health consultations increased 2.7-fold from 1.2 per 
1000 in 2009 to 3.2 per 1000 in 2015 ( N = 84 in 2005 to 500 
in 2015). These data indicate that despite national survey data 
suggesting the rate of adolescent marijuana use is flat, there 
has been a significant increase in adolescent ED/UC visits with 
cannabis-associated ICD codes or positive urine drug screens.9 
Figure 4 displays these visits by year.
Cannabis Effects on Mental Health
Psychosis and Schizophrenia
Previous studies, including large reviews by the World 
Health Organization (WHO) and the National Academies of 
Sciences, Engineering, and Medicine (NASEM), have found 
substantial evidence of a statistical association between cannabis 
use and the development of schizophrenia or other psychoses, 
with the highest risk among the most frequent users.6,10 In a 
study of 45,570 Swedish men drafted into the military, the 
authors found that the men who had tried cannabis by age 18 
were 2.4 times (95% CI, 1.8-3.3) more likely to be diagnosed 
with schizophrenia over the next 15 years than those who had 
not.11 A follow-up study found a dose-response relationship 
between frequency of cannabis use at the age of 18 and the 
risk of schizophrenia. This effect persisted after controlling for 
confounding factors such as psychiatric diagnosis at enlistment, 
IQ score, personality variables concerned with interpersonal 
relationships, place of upbringing, paternal age, cigarette 
smoking, disturbed behaviors in childhood, history of alcohol 
misuse, family history of psychiatric illness, financial situation 
of the family, and father’s occupation. (The enlistment procedure 
Figure 2. Marijuana use in the past month in Kansas, by age group. 
Reproduced from Substance Abuse and Mental Health Services Administration National Survey on Drug Use and Health: State 
Estimates. Available at: https://pdas.samhsa.gov/saes/state. Accessed November 2018.
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included intelligence tests and non-anonymous, self-reported 
questionnaires on family, social background, behavior during 
adolescence, and substance use – including first drug used, drug 
most commonly used, frequency of use, and direct questions 
regarding use of a list of specified drugs.) The researchers 
estimated that 13% of cases of schizophrenia could have been 
averted if no one in the cohort had used cannabis.12 These findings 
have been reproduced repeatedly and across the world.13-20 
Depression, Anxiety, and Suicide
Cannabis use is associated with increased rates of depression, 
anxiety, and suicide. The NASEM found that there is a moderate 
statistical association between cannabis use and an increased risk 
for the development of depressive disorders (odds ratio [OR] 
= 1.17; 95% CI, 1.05-1.30) and this increases with increased 
frequency of use (OR = 1.62; 95% CI, 1.21-2.16).10,21 There 
was also moderate evidence of a statistical association between 
regular cannabis use and increased incidence of social anxiety 
disorder (OR = 1.28; 95% CI, 1.06–1.54).10,22 The NAESM found 
that there was moderate evidence of a statistical association 
between cannabis use and the incidence of suicidal ideation (OR 
= 1.43; 95% CI, 1.13-1.83 with any cannabis use, OR = 2.53; 
95% CI, 1.00-6.39 with heavy cannabis use) and suicide attempts 
(OR = 2.23; 95% CI, 1.24-4.00 for any cannabis use, OR = 3.20; 
95% CI, 1.72–5.94 with heavy cannabis use), and increased 
incidence of suicide completion (OR = 2.56; 95% CI, 1.25–5.27 
for any cannabis use).10,23 
The NASEM reviewed multiple studies to come to the 
summary conclusions, and the odds ratios represent the most 
compelling systematic review for the conclusions. However, there 
were many more studies used to reach the stated conclusions. 
The data reviewed by the World Health Organization also 
demonstrate similar results for depression, anxiety, and suicide.6 
Both the NASEM and the WHO reviews acknowledge that 
reverse causation and shared risk factors cannot be ruled out as 
explanations of these statistical associations and acknowledge 
that further research is needed.
In the most recent data on Colorado adolescent suicides, 
marijuana was the most common substance present for ages 
10-19 in 2016. Of 62 suicides with toxicology data available, 
marijuana was present in 30.6% (n = 19) compared to 9.7% (n = 
6) for alcohol.24 This trend has been increasing since liberalization 
of marijuana policy in 2010. This is more concerning as 
suicide is currently the leading cause of death of adolescents 
in Colorado.25 For all age groups in Colorado, in the five-year 
period from 2004-2009 there were 4822 suicides and 7.1% (n 
Figure 3. Rates of hospitalizations (HD) and emergency department (ED) visits per year with possible marijuana exposures, diagnoses, 
or billing codes per 100,000 HD and ED visits, by legalization eras in Colorado.
Reproduced from Marijuana Legalization in Colorado: Early Findings. A Report Pursuant to Senate Bill 13-283. Colorado Department of  
Public Safety. 2016. Available at: http://cdpsdocs.state.co.us/ors/docs/reports/2016-SB13-283-Rpt.pdf. Accessed March 2018.
NA, Data not available.
Data provided by Colorado Hospital Association with analysis provided by Colorado Department of Public Health and Environment.
Note: Data for 2015 covers January 1, 2015 – June 30, 2015. An individual can be represented more than once in the data; therefore, the rate 
is HD or ED visits with marijuana codes per 100,000 total HD or ED visits. 
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= 303) of those were marijuana positive on toxicology analysis 
(538 did not have toxicology data available). In the subsequent 
five-year period of marijuana legalization, 2010-2015, there were 
5880 total suicides (22% increase), and 12.6% had a positive 
toxicology for marijuana (n = 601; 1,120 did not have toxicology 
data available). This represents a statistically significant 77.5% 
increase in the proportion of suicide victims with toxicology 
positive for marijuana (an absolute difference of 5.5%) for which 
toxicology data were reported (chi square 77.2884, p<0.0001). 
Suicides with marijuana toxicology by year and overall suicide 
by year data are displayed in Figure 5.
Social Outcomes
Cannabis has been associated with adverse social outcomes 
which may impact EDs and patient health. The large (N = 
49,321) cohort study of Swedish men drafted at age 18-20 and 
followed to age 40 showed increased risk of unemployment 
and need for welfare assistance in those using cannabis greater 
than 50 times (risk ratio [RR] = 1.26; 95% CI, 1.04–1.53 for 
unemployment), (RR = 1.38; 95% CI, 1.19–1.62 for welfare 
assistance).26 These results were repeated in a longitudinal birth 
cohort study in New Zealand to 25 years old, which found high 
levels of cannabis use correlated with statistical significance to 
poorer educational outcomes, lower income, greater welfare 
dependence and unemployment, and lower relationship and life 
satisfaction. This cohort was classified into six levels of cannabis 
use, and found that as cannabis use increased, the odds ratio of 
adverse outcome increased.27,28 Both of these studies adjusted for 
confounding factors including socioeconomic background of the 
family, family functioning and exposure to adversity, exposure 
to child sexual and physical abuse, childhood and adolescent 
adjustment, academic achievement in early adolescence, 
comorbid mental health disorders, and other substance use. 
A prospective cohort study from upstate New York (N = 548) 
found that, compared with cannabis nonusers or minimal users (a 
few times a year or less), chronic users and users who began use 
in early adulthood and then tapered off use into later adulthood, 
had a significantly higher likelihood of unemployment at mean 
age 43 (adjusted OR = 3.51; 95% CI, 1.13–10.91), even after 
controlling for covariates.29 The NASEM review stated that there 
was a limited level of evidence of impaired academic achievement 
and education outcomes, increased rates of unemployment and/
or low income, and impaired social functioning or engagement in 
developmentally appropriate social roles.10 The report stated that 
although there was evidence to suggest these outcomes, it was 
difficult to document a direct link between cannabis use and these 
outcomes because other variables played a role. Social outcome 
data for cannabis users specifically in Colorado are currently 
unavailable and could be an area for further research.
Structural, Functional, and Chemical Brain Changes in 
Cannabis Users
A number of review articles on cannabis have described 
adverse effects on brain imaging.6,30-33 These findings may help 
establish a mechanistic link between the epidemiological studies 
on the adverse effects of cannabis. Structural, functional, and 
chemical changes to the brain have been established. These 
include both the gray matter (neuronal cells) and white matter 
(nerve axons responsible for communication).34,35 Structural 
changes to the brain include reductions in the hippocampus34-38 
(12.1% in the left and 11.9% in the right, relative to controls)38 
and amygdala37,38 (6.0% in the left and 8.2% in the right, relative 
to controls)38 volumes in cannabis users. 
Several studies also identified reductions in volume of 
Figure 4. Number of emergency department (ED)/urgent care (UC) visits with cannabis-associated International Classification of Diseases 
codes or positive urine drug screens by adolescents aged 13 to < 21 to a tertiary-care children’s hospital system in Colorado by year.105
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specific areas of the prefrontal cortex,39-41 as well as functional 
magnetic resonance imaging (fMRI) studies demonstrating 
reduced functional connectivity in the prefrontal networks 
responsible for executive function (including inhibitory 
control) and the subcortical networks, which process 
habits and routines.30,42-25 Other fMRI studies show reduced 
connectivity in the fimbriae of the hippocampus and 
commissural fibers extending to the precuneus, and suggest 
that this disturbed brain connectivity in cannabis users may 
underlie cognitive impairment and vulnerability to psychosis, 
depression, and anxiety disorders.46 Multiple other areas of the 
brain have also been shown to demonstrate changes on fMRI 
studies in response to cannabis and include the orbitofrontal 
cortex, anterior cingulate cortex, striatum, amygdala, 
hippocampus, and cerebellum.37 In general, these changes on 
both structural and functional MRI studies corresponded with 
frequency of use and earlier age of onset of use (although 
several studies identified these changes in adult users as 
well).34,35 
Changes to neurotransmitters in the brain have also been 
well described in systematic reviews and include disruptions 
in glutamate,47 dopamine,48 N-acetylaspartate,49 myo-inositol,49 
choline,49 and γ-aminobutyric acid (GABA).33,49
Taken together, these changes may underlie the clinical 
features being observed in observational and epidemiological 
studies demonstrating increases in psychosis, impulsivity, 
depression, anxiety, suicidality, decreases in cognition, IQ, and 
executive function, abnormalities in habits, routines, decision-
Figure 5. Suicides with marijuana toxicology by year and total suicides by year in Colorado (A). Percent of suicides with marijuana 
present by year (B).24
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Year
Suicides with marijuana present Total suicides
0
20
40
60
80
100
120
140
160
180
N
um
be
r o
f s
ui
ci
de
s 
w
ith
 m
ar
iju
an
a 
pr
es
en
t
700
750
800
850
900
950
1000
1050
1100
To
ta
l n
um
be
r o
f s
ui
ci
de
s
0%
2%
4%
6%
8%
10%
12%
14%
16%
Year
Percentage of suicides positive for marijuana
Pe
rc
en
t o
f s
ui
ci
de
s 
w
ith
 m
ar
iju
an
a 
pr
es
en
t
Volume 20, no. 4: July 2019 563 Western Journal of Emergency Medicine
Roberts Legalized Cannabis in Colorado EDs: Negative Health and Safety Effects
making capacity, and deficits in learning, memory, attention, 
and social interaction.6,30,31 
Link to Other Substance Abuse
Cannabis use has also been associated with abuse of other 
illicit substances. According to the NASEM report, there is a 
moderate level of evidence of a statistical association between 
cannabis use and the development of substance dependence 
and/or substance abuse disorder for alcohol, tobacco, and 
illicit drugs.10 Multiple cohort studies have demonstrated these 
results.50-52 Four separate discordant twin studies have found 
that the twin who used marijuana was more likely to use 
other substances even after controlling for environmental and 
genetic influences.53-56 Although some studies reported that 
medical cannabis has resulted in improvements in opiate-related 
deaths,57,58 Colorado has had an increase in poisoning and deaths 
from opiates and methamphetamines since 2010, with the 
highest in 2017. These rates have increased nationwide as well 
and the influence of cannabis in Colorado is difficult to discern. 
Nevertheless, the increase in overdose deaths in Colorado is 
alarming. These data are shown in Figure 6.25
Although animal studies do not consistently translate to 
human effects, rat studies can provide some mechanistic clues. 
After exposure to tetrahydrocannabinol (THC), rats have an 
increased behavioral sensitization response to not only THC 
but also opiates and nicotine.59-61 Studies also demonstrate 
that these behavioral changes in rats correspond to neuronal 
activity changes in mesolimbic dopamine neurons in the 
ventral tegmental area and nucleus accumbens and that cross-
tolerance results with exposure to morphine, amphetamines, and 
cocaine.61,62 Repeat morphine self-administration has been shown 
to be significantly lower in CB1 knockout mice (CB1 receptors are 
the among the most predominant G protein-coupled receptors in 
the brain and mediate most of the psychotropic effects of THC) 
and opiate withdrawal symptoms significantly less when the 
knockout mice are administered naloxone.63 
Cannabis Dependence/Withdrawal Symptoms
Cannabis use may result in dependence and cessation may 
result in withdrawal symptoms. Dependence rates are reported 
at one in 10 among those who ever use cannabis, one in six 
among adolescent users, and one in three among daily users.6,64-67 
Withdrawal symptoms may include anxiety, insomnia, appetite 
disturbance, and depression. These symptoms are sufficient to 
impair everyday functioning and are markedly attenuated by 
doses of an oral cannabis extract.6 
Other Relevant Physiological and Safety Concerns with 
Cannabis
Cannabinoid Hyperemesis Syndrome
Cannabinoid hyperemesis syndrome (CHS) has been 
well described in the literature.68-70 The symptoms of CHS 
include significant nausea, violent vomiting, and abdominal 
pain in the setting of chronic cannabis use. Cardinal diagnostic 
characteristics include regular cannabis use, cyclic nausea and 
vomiting, and compulsive hot baths or showers with resolution 
of symptoms after cessation of cannabis use.69 CHS patients 
present similarly to cyclic vomiting syndrome patients with the 
exception that cannabis use is required to make the diagnosis.69 
Following legalization, the prevalence of cyclic vomiting 
presentations to Denver Health and the University of Colorado 
Hospital increased 1.92-fold (95% CI, 1.33 to 2.79) from 41 per 
Figure 6. Drug poisoning/overdose deaths in Colorado by involvement of specific drug type: Colorado residents, 1999-2017.*
Reproduced from: Vital Statistics Program, Colorado Department of Public Health and Environment. Available at: https://drive.google.
com/file/d/1vfi4kL9eD9rib7aEboteiGw67gOxXFpf/view. 
*Drug categories are not mutually exclusive; a death involving more than one type of specific drug will be counted in each applicable 
category. “Fentanyl” is a subset of “prescription opioid.”
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113,262 ED visits from a year prior to marijuana liberalization 
(November 1, 2008–October 31, 2009) to 87 per 125,095 
ED visits a year following marijuana liberalization (June 1, 
2010–May 31, 2011). Patients with cyclic vomiting in the 
post-liberalization period were more likely to have marijuana 
use documented than patients in the pre-liberalization period 
(OR = 3.59; 95% CI, 1.44 to 9.00).71 These patients often are 
evaluated with multiple imaging studies, lab work, endoscopies, 
and admissions to the hospital as well as antiemetic treatment. 
These studies are often non-diagnostic and treatment is often 
ineffective. This may also influence ED crowding.68,72 
Motor Vehicle Collisions
Traffic fatalities with blood or urine drug screens positive 
for cannabinoids have sharply risen across Colorado.73,74 Total 
fatal motor vehicle collisions (MVC) in Colorado had been 
decreasing from a high of 677 in 2002 to a low of 407 in 2011 but 
then began increasing each year since then to 600 in 2017. Total 
MVCs mirror this trend. The NASEM review found substantial 
evidence of a statistical association between cannabis use and 
increased risk of MVCs.10 CDPHE found substantial evidence 
that recent marijuana use by a driver increases his or her risk of a 
MVC and that the higher the blood THC level, the higher the risk 
of MVC. The use of alcohol and marijuana together increases risk 
of impairment and MVC more than either substance alone. For 
less-than-weekly marijuana users, using marijuana containing 10 
milligrams (mg) of THC is likely to impair the ability to safely 
drive, bike, or perform other safety-sensitive activities. A typical 
marijuana cigarette, or joint, contains 60-115 mg of THC.75 
A systematic review of observational studies and meta-
analysis for acute cannabis consumption and MVC risk found 
that driving under the influence of cannabis was associated with a 
significantly increased risk of MVCs compared with unimpaired 
driving (OR = 1.92; 95% CI, 1.35 to 2.73), especially for fatal 
collisions (OR = 2.10; 95% CI, 1.31 to 3.36).76 However, a 
recent study of crash fatality rates after recreational marijuana 
legalization in Washington and Colorado found changes in motor 
vehicle crash fatality rates were not statistically different from 
those in similar states without recreational marijuana legalization. 
This was, however, only after further statistical regression 
analysis (for population, gender, spending on road construction 
and maintenance, annual gross domestic product, per capita 
income, unemployment rate, per capita alcohol consumption, 
seatbelt laws, road density, traffic density, and rurality). Initial 
data demonstrated that after legalization, motor vehicle crash 
fatality rates increased by a mean of +0.1 (± 0.4) fatalities per 
billion vehicle miles traveled in Washington and Colorado, and 
decreased by a mean of -0.5 (± 0.9) fatalities per billion vehicle 
miles traveled in the control states each year.77 
Cardiovascular Effects
The effect of cannabinoids on the cardiovascular system 
is complex and an area of ongoing research.78 Of concern to 
practicing emergency physicians is ST-segment elevation 
myocardial infarctions and acute stroke presentations with a 
close temporal relationship with cannabis use, which have been 
documented in multiple case reports in otherwise young, healthy, 
male patients.79-82 The NASEM summary found there was a 
limited level of evidence of a statistical association between 
acute cannabis use and triggering an acute myocardial infarction 
(AMI), ischemic stroke, or subarachnoid hemorrhage.10 The 
WHO review states: “There is evidence that cannabis use can 
trigger coronary events. Recent case reports and case series 
suggest that cannabis smoking may increase cardiovascular 
disease risk in younger cannabis smokers who are otherwise at 
relatively low risk.”6 
CDPHE found moderate evidence that marijuana use 
increases risk of ischemic stroke in individuals younger than 
55 years of age and limited evidence that acute marijuana use 
increases risk of myocardial infarction.75 The main case crossover 
study cited for the AMI findings demonstrated that the risk for 
AMI associated with cannabis use during the hour preceding 
symptoms of AMI was elevated 4.8 times over baseline (95% CI,  
2.9-9.5). This risk was substantially reduced following that hour.83
A review of nationwide inpatient sample data from 2010 
to 2014 demonstrated a 32% increase in inpatient admissions 
for primary diagnosis of myocardial infarction and secondary 
diagnosis of cannabis use disorder (increasing from 2198 to 2900 
cases). The overall mean age of patients was 41 years old. These 
patients also had longer lengths of stay, higher hospitalization 
costs, and higher levels of morbidity due to AMI following 
hospitalization than non-cannabis users.84 
In a study reviewing secondhand marijuana smoke exposure, 
the authors found that one minute of exposure substantially 
impaired endothelial function in rats for at least 90 minutes, 
considerably longer than comparable impairment by tobacco 
secondhand smoke.85
The pathophysiological basis of these events is not 
fully understood and a full discussion is beyond the scope 
of this review. In short summary, it may encompass a 
complex interaction between exogenous cannabinoids and 
the endocannabinoid system, autonomic nervous system, 
oxidative stress, direct cellular effects on the endothelium, and 
pro-coagulant effects.86 Exposure to THC causes activation 
of the sympathetic nervous system and inhibition of the 
parasympathetic nervous system.87 These effects include 
elevated heart rate, serum norepinephrine levels, elevated 
supine blood pressure, and increases in left ventricular 
systolic function87-89 Smoking results in decreasing oxygen 
delivery to the heart and other vital organs and may be further 
compromised by increasing carboxyhemoglobin levels.90 
The impaired myocardial oxygen demand-to-supply ratio 
following cannabis smoking has been shown to reduce the 
time to onset of symptoms during exercise in patients with 
stable angina.91 
Direct effects of cannabis on blood vessels are complex 
due to the differing compounds in cannabis and the functional 
properties of the blood vessels examined.92 Studies are 
Volume 20, no. 4: July 2019 565 Western Journal of Emergency Medicine
Roberts Legalized Cannabis in Colorado EDs: Negative Health and Safety Effects
inconsistent regarding the effects on vasoconstriction and 
dilation. Cannabis has been consistently shown to produce 
vasodilation with resultant orthostatic hypotension,92,93 
but it has also been implicated in vasoconstrictive arteritis 
mechanisms.94,95 A large review article suggested that there 
are three phases in cardiovascular parameters affected by 
the endocannabinoid system and that different chemical 
constituents of the cannabis plant have varying effects 
at different target organs, which may account for the 
differences.93 Transient vasospasm and reduction in cerebral 
blood flow are well described and may underlie changes in 
coronary, cerebral, and peripheral arterial systems leading to 
end organ ischemia.86,96,97 Myocardial blood flow has been 
shown to correlate inversely with circulating plasma levels of 
endocannabinoids.86,98 Cannabis has also been shown to be a 
potent source of cellular oxidative stress through formation of 
reactive oxygen species, and this may contribute to endothelial 
dysfunction and promote regional arterial vasospasm.86,99 
THC has also recently shown a dose-dependent pro-
coagulant effect.100 This ex vivo observation has been 
supported by reports of thrombotic coronary artery occlusion 
in young individuals without underlying atherosclerosis.86 
There are also cannabinoid receptors on the surface of 
platelets and THC has been shown to increase the surface 
expression of glycoprotein IIb–IIIa and P selectin in a 
concentration-dependent manner resulting in platelet 
activation.86,101 Figure 7 summarizes these effects.
Respiratory Effects
Marijuana smoking leads to adverse pulmonary 
outcomes. The NASEM, CDPHE, and WHO reports state 
there is substantial evidence of a statistical association 
between marijuana smoking and worse respiratory symptoms 
and more frequent chronic bronchitis episodes.6,10,75 These 
data were based primarily on a systematic review by 
Tetrault et al. from 14 studies that assessed the association 
between long-term cannabis smoking respiratory symptoms 
including chronic cough (OR = 1.7–2.0), increased sputum 
production (OR = 1.5–1.9), and wheezing (OR = 2.0–3.0).102 
There is also evidence of a statistical association between 
the cessation of cannabis smoking and improvements in 
respiratory symptoms.10 Cannabis smoking may also lead 
to increased rates of pneumonia and upper respiratory 
infections. On histology, this is associated with a reduction 
in ciliated cells and increase in mucus secretion from the 
larger number of mucus-secreting cells.6,30,103
Exposures to Children
Reported exposures to children less than age 10 have 
sharply increased in Colorado following recreational marijuana 
legalization. A retrospective cohort study of hospital admissions 
and regional poison control center (RPC) cases between January 
1, 2009–December 31, 2015 at a tertiary-care children’s hospital 
found that the mean rate of marijuana-related visits to the 
children’s hospital (ages 0-9) increased from 1.2 per 100,000 
population in the two years prior to legalization to 2.3 per 
Figure 7. Flow diagram demonstrating pathophysiologic pathways to common major adverse cardiovascular events reported in users of 
cannabis and related chemicals.86
AMI, acute myocardial infarction; CBR1, cannabinoid receptor 1; CVA, cerebrovascular accident; MVO2 myocardial oxygen consumption 
(demand); O2, oxygen; ROS, reactive oxygen species.
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100,000 after (P = .02). The median age of exposure was 2.4 
years. The majority were exposure to an infused edible product 
(48%, n = 30); 65% (n = 40) were observed in the ED or UC; 
21% (n = 13) were admitted to an inpatient ward; and 15% (n 
= 9) were admitted to the intensive care unit. Two of these 
children required respiratory support. The median length of 
stay for all patients was 11 hours, and the median length of 
stay for admitted patients was 26 hours. 
Annual RPC pediatric marijuana cases increased more 
than five-fold from 2009 (nine cases) to 2015 (47 cases).104 
Colorado had an average increase in RPC cases of 34% 
(P < .001) per year while the remainder of the United States 
had an increase of 19% (P < .001).104 In a follow-up study in 
October 2018, the same author found that despite multiple 
public health interventions in legislation after 2014 (child-
resistant packaging, dose limitations, opaque packaging, 
limiting marketing campaigns, and banning specific edibles), 
the incidence of children’s hospital visits and RPC calls has 
continued to rise in Colorado with an observed doubling of 
children’s hospital visits in 2017 compared to 2016105 (Figure 
8). Edibles are sold as cookies, candies, and sodas with 
advertising that appeals to children.104,106
Cannabis Contaminants, Cannabis Concentrates, and Hash-oil 
Burns
Varying cultivation techniques and end-product 
alterations further complicate the understanding of the 
physiological effects of cannabis. Cannabis plants can be 
altered to achieve higher growth rates, changes in potency, 
and increased bud production. These techniques can include 
use of varying soil types, fertilizers, and pesticides that 
can result in physiological effects. These changes may 
also result in exposures to possible fungal agents such as 
powdery mildew and botrytis; budworm or mite infestations 
have been reported in the literature. Historically, there have 
been reports of bacterial contamination with salmonella, 
enterobacter, streptococcus, and klebsiella, as well as case 
reports of fungal spore contaminants, including mycotoxin‐
producing strains of aspergillus.107 
There are three pathways through which cannabis may 
be contaminated with heavy metal substances. Firstly, 
cannabis is able to remove heavy metals from substrate 
soils and deposit these in its tissues by virtue of its 
bioaccumulative capacity. Secondly, cross‐contamination 
may occur during processing (eg, during drying). Thirdly, 
post‐processing adulteration may occur, whereby metals may 
be added to the preparation to increase weight and thereby 
appreciate its street value. There are case reports of lead 
and arsenic poisoning from cannabis.107 Pesticides are also 
commonly used in cannabis cultivation. In a report from 
Washington State, laboratory analysis revealed that 84.6% 
(N = 26 samples) of legalized cannabis products contained 
significant quantities of pesticides including insecticides, 
fungicides, miticides, and herbicides. These comprised a 
wide array of different substances and encompassed proven 
carcinogens (carbaryl, diuron, ethoprophos, permethrin, and 
propargite), endocrine disruptors, as well as a variety of 
developmental, reproductive, and neurological toxins. 107,108 
There are also changes in end-product concentrations 
through post-processing of the plant. These changes include 
creation of oils, waxes/shatter, and dabs. Oils are created by 
removing the hydrophobic components such as THC with a 
heated butane solvent. THC concentrations may reach up to 
55.7%.109 Waxes and shatter are concentrated and solidified 
oil with THC concentration reaching up to 90% THC. 110,111 
Dabs are composed of heated wax and are inhaled off of an 
Figure 8: Colorado pediatric marijuana exposures (ages 0-9) to a tertiary-care children’s hospital, and regional poison control center 
cases by year.105
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object such as a nail, which even further concentrates THC 
content over 90%.112 
Preparation of these concentrated products has also led 
to fires and explosion injuries in amateur production attempts 
in garages, tool sheds, and vacant homes.113,114 In Colorado 
29 patients with butane hash-oil burns were admitted to the 
University of Colorado Burn Center from 2008-2014. Zero 
cases presented prior to medical liberalization, 19 during 
medical liberalization (October 2009–December 2013), and 
12 from January–June 2014 at the study’s conclusion. (Two 
patients had four total visits.) The median total body surface area 
(TBSA) burn size was 10% (TBSA range 1-90%). Median length 
of hospital admission was 10 days. Six required intubation for 
airway protection while 19 required skin grafting.115 
Marijuana Shop Employees Providing Medical Advice
Marijuana shop employees not trained in medicine 
or pharmacology are giving medical advice that may be 
harmful to patients. A recent study in Colorado found that 
employees are giving medical advice 70% of the time 
to use cannabis for treatment of nausea and vomiting in 
pregnancy and few dispensaries encouraged discussion 
with a healthcare provider without prompting.116 The author 
has personally had patients bring in products recommended 
by dispensary workers with a recommended potency and 
frequency of use and report being advised to stop their 
usual medications and use the cannabis product instead. 
Cannabis dispensaries provide medical advice and offer 
treatment without medical training even when this may 
harm the patient.
Potential Medicinal Uses of Cannabis
There are potential therapeutic intervention targets for 
cannabinoids. In general, these therapeutic targets require 
a high ratio of cannabidiol compounds (CBD- cited to 
decrease or eliminate the psychoactive effects of THC), and 
are from products that significantly differ from those found 
in commercial dispensaries. The NASEM report found 
substantial evidence that cannabis or cannabinoids are 
effective for the treatment of chronic pain in adults, as an 
antiemetic for chemotherapy-induced nausea and vomiting, 
and for improving patient-reported multiple sclerosis 
spasticity symptoms. They also found moderate evidence 
that cannabis or cannabinoids are effective for improving 
short-term sleep outcomes associated with obstructive sleep 
apnea, fibromyalgia, chronic pain, and multiple sclerosis.10 
Studies have also demonstrated that cannabinoids may 
improve cardiovascular outcomes.92,117 
Likely the most significant treatment implication has 
been in patients with refractory epilepsy, most commonly 
in patients with Dravet’s syndrome and Lennox-Gestault 
syndrome, but also in other patients. This has led to the 
U.S. Food and Drug Administration approving Epidiolex 
(a high concentration CBD cannabinoid treatment) in 
June 2018 for the treatment of Dravet’s syndrome and 
Lennox-Gestault syndrome.118-120 Despite these potential 
medicinal uses, current Colorado legal distribution of 
cannabis products goes through an intermediary budtender 
before making it to the patient which may not consistently 
promote therapeutic benefit; there is insufficient training of 
dispensary staff to serve this purpose.
Variations in Potency, Bias in Studies, and Conflicting 
Laws Confuse Consumers and Impair Research
The potential positive health effects of cannabis rest on 
which of the multiple species and hybrids are studied and 
their specific chemical composition. One of the difficulties 
in determining the physiological effects of cannabis is that 
“marijuana,” or “cannabis,” can refer to multiple species 
of plants with widely varying chemical compounds and 
corresponding variable physiological effects. The cannabis 
genus includes multiple species, most commonly Cannabis 
sativa and Cannabis indica, and within those are hybrids 
specifically developed by growers to achieve a specific 
effect. For example, the commonly used term, hemp, refers 
to a variety of Cannabis sativa that is fast growing and 
can be spun into usable fiber for paper, textiles, clothing, 
biofuel, animal feed, and other industrial uses. Hemp has 
low concentrations of THC (less than 0.3%) and higher 
concentrations of CBD. 
The differences in composition offer different potential 
treatment effects. For example, the effect for pain control 
cited in the NASEM review was primarily found with 
nabiximols (Sativex), a cannabis extract mouth spray that 
delivers a dose of 2.7 mg of THC and 2.5 mg of CBD.121 
For comparison, a typical marijuana cigarette or joint 
contains 0.5 g of marijuana and THC content ranges from 
12-23%; therefore, a typical joint contains 60-115 mg 
of THC, 20-40 times the medicinal dose. The NASEM 
cautioned that many of the cannabis products sold in state-
regulated markets bear little resemblance to those available 
for research at the federal level in the U.S.10 This is further 
complicated in that commonly sold cannabis products are 
often mislabeled for CBD and THC content. One study 
showed only 17% of dispensary products were accurately 
labeled. 122,123 Scientific studies, particularly for treatment 
of pain, have been limited by a substantial bias, and results 
have varied.124,125 Some demonstrate improvement in pain10 
with coinciding decreases in opiate abuse,10,57,126 while 
others show the opposite.123,125,127,128 
The conflict between federal and state laws on the 
medical use of cannabis products, the lack of consistency 
among state laws, and the availability of artisanal products 
in dispensaries, with high variability between composition 
of products, have caused significant confusion for 
researchers and limited the ability to fully and accurately 
research the true effects of commonly available dispensary 
cannabis products.129 
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LIMITATIONS
This was not a systematic review of the literature but 
rather a summary of selected research including several large 
reviews from the NASEM, the WHO, and the CDPHE. There 
is undoubtedly much literature, some of it conflicting, not 
cited here. However, as other states and countries wrestle with 
decriminalization and legalization of cannabis for personal 
use and sale, it is crucial to report the Colorado experience 
as a cautionary tale. This review summarizes a large body 
of research for practicing emergency physicians who are 
increasingly confronted with questions and patients who 
use cannabis. Although the author practices in Colorado, the 
information is likely generalizable. This review clearly reflects 
the author’s biases, yet its composition was motivated by 
alarming experience in everyday practice.
Discussions of cannabis’ effects are relevant not only to 
the healthcare system, but to legal, business, environmental, 
legislative, and other branches within a public health 
framework. This article does not address those other facets. 
Neither have numerous other physiological effects of cannabis 
been reviewed here. Many of the previous research studies 
have focused on cannabis with a much lower THC level 
limiting applicability to cannabis sold at dispensaries today. 
Finally, the words “marijuana” and “cannabis” were used 
interchangeably throughout the article. This was done to 
maintain the wording from the studies cited consistent with 
their original language. No difference should be implied with 
the alternating use of these terms. 
CONCLUSION
Cannabis legalization has led to significant health 
consequences, particularly to EDs and hospitals in Colorado. The 
most concerning include psychosis, suicide, and other substance 
abuse. There are deleterious effects on the brain and some of 
these may not be reversible with abstinence. Other significant 
health effects include increases in fatal motor vehicle collisions, 
adverse effects on cardiovascular and pulmonary systems, 
inadvertent pediatric exposures, cannabis contaminants exposing 
users to infectious agents, heavy metals, and pesticides, and 
hash-oil burn injuries due to preparation of concentrates. Finally, 
cannabis dispensary workers not trained in medicine are giving 
medical advice that could be harmful to patients. 
Cannabis research may offer opportunities for novel 
treatment of seizures, spasticity from multiple sclerosis, 
nausea and vomiting from chemotherapy, chronic pain, 
improvements in cardiovascular outcomes, and sleep 
disorders. However, progress has been difficult due to absent 
standardization of the chemical composition of cannabis 
products and limitations on research secondary to federal 
classification of cannabis. Given these factors and the 
Colorado experience, other states should carefully evaluate 
whether and how to decriminalize or legalize non-medical 
cannabis use.
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